Athira Pharma (NASDAQ:LONA) vs. Inhibikase Therapeutics (NASDAQ:IKT) Head to Head Analysis

Athira Pharma (NASDAQ:LONA) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap manufacturing companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, earnings, dividends and risk.

Earnings and Valuation

This table compares Athira Pharma and Inhibikase Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$96.94 million	($9.68)	-1.17
Inhibikase Therapeutics	$260,000.00	568.77	-$27.52 million	($0.39)	-5.04

Inhibikase Therapeutics has higher revenue and earnings than Athira Pharma. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 25.1% of Athira Pharma shares are held by insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Athira Pharma and Inhibikase Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-107.06%	-89.89%
Inhibikase Therapeutics	N/A	-57.15%	-52.76%

Analyst Recommendations

This is a summary of current ratings for Athira Pharma and Inhibikase Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1	1	2	0	2.25
Inhibikase Therapeutics	1	1	2	4	3.13

Athira Pharma currently has a consensus price target of $10.00, suggesting a potential downside of 11.50%. Inhibikase Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 179.61%. Given Inhibikase Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Athira Pharma.

Volatility and Risk

Athira Pharma has a beta of 2.68, meaning that its stock price is 168% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Summary

Inhibikase Therapeutics beats Athira Pharma on 8 of the 12 factors compared between the two stocks.

About Athira Pharma

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company’s lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer’s disease, as well as is in Phase 2 clinical trials to treat Parkinson’s disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.